



CHEPLAPHARM BUYS THE RIGHTS FOR SEROQUEL® AND SEROQUEL XR® IN EUROPE (EXCLUDING THE UK) AND NORTH AMERICA

Greifswald, 01/31/2020 – AstraZeneca and CHEPLAPHARM have agreed to transfer the commercial rights for SEROQUEL® and other related brands for the North American and the European Market (excluding the United Kingdom) to CHEPLAPHARM. This is another important acquisition of a well-known global branded product for CHEPLAPHARM in 2019.

“This investment points out that we are able to achieve the milestones we set ourselves, especially in terms of sales and earnings”, said CHEPLAPHARM’s CEO Sebastian F. Braun.

The respective acquisition includes the brands SEROQUEL®, SEQUASE® and ALZEN® (API: quetiapine fumarate) and refer to the class of atypical antipsychotics. These are prescribed for schizophrenia, bipolar disorders and depression, which affect about 300 million people globally.

Until all acquired marketing authorizations in the respective countries have been transferred to CHEPLAPHARM, the production and distribution will be ensured by the seller.

About CHEPLAPHARM

CHEPLAPHARM is a pharmaceutical company headquartered in Greifswald, Germany, offering branded and niche products in more than 120 countries worldwide. The family-owned company specializes in selected active substances and indications and focuses on an international buy-and-build strategy. Working closely with its business partners, CHEPLAPHARM achieves sustainable annual growth rates. CHEPLAPHARM has been one of the fastest-growing pharmaceutical companies in Europe for years with projected annual sales of 650 million euros in 2020.

Please refer to www.cheplapharm.com for additional information.

Press office:

CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | [presse\(at\)cheplapharm.com](mailto:presse(at)cheplapharm.com)